Drugs / zuojinwan
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06901375 | May → Aug 2025 | Helicobacter pylori infectious disease | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06481371 | Jun 2024 → Feb 2025 | depressive disorder, dyspepsia | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
| — | NCT06481787 | Jun 2024 → Apr 2026 | depressive disorder, gastroesophageal reflux disease | Nanjing First Hospital, Nanjing Medical University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | zuojinwan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481371 ↗ |
| Known as | Zuojin Pills | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06481787 ↗ |
| Route | Oral | “Zuojin Wan 3 g tablet orally twice daily” NCT06901375 ↗ |